1. ANCA-positive pauci-immune glomerulonephritis and febuxostat treatment
- Author
-
Gilbert Deray, Philippe Rouvier, Hassane Izzedine, Henri Boulanger, and Victor Gueutin
- Subjects
medicine.medical_specialty ,Nausea ,Pharmacology ,Gastroenterology ,chemistry.chemical_compound ,Internal medicine ,medicine ,Xanthine oxidase ,ANCA POSITIVE ,Transplantation ,From the Clinic ,ANCA ,febuxostat ,business.industry ,Glomerulonephritis ,medicine.disease ,Gout ,Educational Papers ,chemistry ,Nephrology ,Pauci-immune ,pauciimmune glomerulonephritis ,Febuxostat ,Liver function ,medicine.symptom ,business ,medicine.drug - Abstract
The approval of febuxostat, a non-purine analogue inhibitor of xanthine oxidase, by the European Medicines Agency and US Food and Drug Administration, heralds a new era in the treatment of gout [1]. The most commonly reported adverse drug reactions were liver function abnormalities, diarrhoea, headache, nausea, and dizziness and/or altered taste. Only one case of cutaneous leukocytoclastic vasculitis has been reported with febuxostat [2]. In this report, we provide the first case of anti-neutrophil cytoplasmic antibody (ANCA)-positive pauci-immune glomerulonephritis (PIGN) during febuxostat treatment.
- Published
- 2012
- Full Text
- View/download PDF